In vivo immortalization of murine peritoneal macrophages: a new rapid and efficient method for obtaining macrophage cell lines

1993 ◽  
Vol 53 (4) ◽  
pp. 475-478 ◽  
Author(s):  
Cecilia Adami ◽  
Michael J. Brunda ◽  
Alicia V. Palleroni
Keyword(s):  
Cell Lines ◽  
Efficient Method ◽  
Peritoneal Macrophages ◽  
Macrophage Cell ◽  
Murine Peritoneal Macrophages

Immunocytochemical Analysis of Murine Peritoneal Macrophages Treated with “Poly-Plat”, an in Vitro and in Vivo Study

1998 ◽  
Vol 4 (S2) ◽  
pp. 1122-1123
Author(s):  
H. J. Muenchen ◽  
S.K. Aggarwal
Keyword(s):  
Immune System ◽  
Mechanism Of Action ◽  
Second Generation ◽  
Peritoneal Macrophages ◽  
In Vivo Study ◽  
Immunocytochemical Analysis ◽  
Murine Peritoneal Macrophages

Poly-[(trans-1,2-diaminocyclohexane) platinumj-carboxyamylose (“poly-plat“) is a second generation analog of cisplatin which enhances the immune system with greater efficacy in vitro and in vivo “Poly-plat” contains 1/5 the platinum of CDDP and demonstrates less toxicity. In order to understand the mechanism of action of this compound an in vitro and in vivo study was performed. Swiss Webster mice and isolated murine peritoneal macrophages were treated with “poly-plat” (10 mg/kg). The Swiss Webster mice were given bolus injections and sacrificed at 2 and 12 days. Peritoneal macrophages were then isolated and allowed to incubate in culture for 24 h. Peritoneal macrophages were also isolated from normal mice and treated with the drugs for 2 h. After treatments the macrophages were placed in fresh media and allowed to incubate 24 h. Supematants were isolated at various times during culture for immunocytochemical analysis.Both in vitro and in vivo studies showed enhanced immunostimulation after their respective treatments.

scholarly journals Constitutive secretion of cystatin C (gamma-trace) by monocytes and macrophages and its downregulation after stimulation.

1987 ◽  
Vol 166 (6) ◽  
pp. 1912-1917 ◽  
Author(s):  
A H Warfel ◽  
D Zucker-Franklin ◽  
B Frangione ◽  
J Ghiso
Keyword(s):  
Cell Lines ◽  
Cystatin C ◽  
Peritoneal Macrophages ◽  
Inflammatory Conditions ◽  
Monocytes And Macrophages ◽  
Constitutive Secretion ◽  
Established Cell ◽  
Mouse Peritoneal Macrophages

Cystatin C (gamma-trace) was found to be a constitutively secreted protein of isolated human monocytes and mouse peritoneal macrophages, as well as the histiocytic lymphoma cell lines U937, P388D.1, and J774. This proteinase inhibitor is not uniquely secreted by monocytes/macrophages, but was also identified in the conditioned media from several primary cells, including brain cells, and diverse established cell lines. In vitro treatment of resident mouse peritoneal macrophages with either LPS or IFN-gamma caused a downregulation in cystatin C secretion. Elaboration of this protein was also diminished by macrophages that had been stimulated by thioglycollate in vivo, and treatment of these cells with LPS led to further decline. It is suggested that, under some inflammatory conditions, downregulation of cystatin C may contribute to tissue pathology.

scholarly journals Atherogenic characteristics of oral sugar-reducing sulfonylurea derivatives

1994 ◽  
Vol 40 (3) ◽  
pp. 8-10
Author(s):  
M. A. Maxumova ◽  
I. A. Sobenin ◽  
M. I. Balabolkin ◽  
A. N. Orekhov
Keyword(s):  
Peritoneal Macrophages ◽  
Cholesterol Levels ◽  
Murine Peritoneal Macrophages ◽  
Sulfonylurea Drugs

The authors have examined the effects of sulfonylurea drugs glybenclamide and glypizide and of their analogs manilil and minidiab on cholesterol levels in murine peritoneal macrophages. Both glybenclamide and glypizide had a direct atherogenic effect on cultured murine peritoneal macrophages. A similar effect was observed in vivo: blood sera of diabetics after a single intake of 5 mg of manilil or minidiab increased the atherogenic potential of cultured murine peritoneal macrophages.

scholarly journals Polysaccharide Isolated From Tetrastigma hemsleyanum Activates TLR4 in Macrophage Cell Lines and Enhances Immune Responses in OVA-Immunized and LLC-Bearing Mouse Models

2021 ◽  
Vol 12 ◽  
Author(s):  
Fang-mei Zhou ◽  
Yu-chi Chen ◽  
Chao-ying Jin ◽  
Chao-dong Qian ◽  
Bing-qi Zhu ◽  
...  
Keyword(s):  
Immune Responses ◽  
Mrna Expression ◽  
Cell Lines ◽  
Mechanistic Study ◽  
Macrophage Cell ◽  
Antitumor Effects ◽  
Tetrastigma Hemsleyanum ◽  
Tlr4 Signaling ◽  
Tlr4 Agonist

Tetrastigmahemsleyanum Diels et Gilg is a valuable Chinese medicinal herb with a long history of clinical application. Our previous study isolated and characterized a purified polysaccharide from the aerial part of Tetrastigma hemsleyanum (SYQP) and found it having antipyretic and antitumor effects in mice. A preliminary mechanistic study suggests these effects may be related to the binding of toll-like receptor (TLR4). The objective of this study is to further explore the detailed stimulating characteristics of SYQP on TLR4 signaling pathway and its in vivo immune regulating effect. We use HEK-BLUE hTLR4, mouse and human macrophage cell lines, as research tools. In vitro results show SYQP activated HEK-BLUE hTLR4 instead of HEK-BLUE Null cells. The secretion and the mRNA expression of cytokines related to TLR4 signaling significantly increased after SYQP treatment in both PMA-induced THP-1 and RAW264.7 macrophage cell lines. The TLR4 antagonist TAK-242 can almost completely abolish this activation. Furthermore, molecules such as IRAK1, NF-κB, MAPKs, and IRF3 in both the MyD88 and TRIF branches were all activated without pathway selection. In vivo results show SYQP enhanced antigen-specific spleen lymphocyte proliferation and serum IgG levels in OVA-immunized C57BL/6 mice. Orally administered 200 mg/kg SYQP induced obvious tumor regression, spleen weight increase, and the upregulation of the mRNA expression of TLR4-related cytokines in Lewis lung carcinoma–bearing mice. These results indicate SYQP can act as both a human and mouse TLR4 agonist and enhance immune responses in mice (p < 0.05). This study provides a basis for the development and utilization of SYQP as a new type of TLR4 agonist in the future.

scholarly journals Design, synthesis and biological evaluation of N-oxide derivatives with potent in vivo antileishmanial activity

PLoS ONE ◽  
2021 ◽  
Vol 16 (11) ◽  
pp. e0259008
Author(s):  
Leandro da Costa Clementino ◽  
Guilherme Felipe Santos Fernandes ◽  
Igor Muccilo Prokopczyk ◽  
Wilquer Castro Laurindo ◽  
Danyelle Toyama ◽  
...  
Keyword(s):  
Parasite Burden ◽  
Peritoneal Macrophages ◽  
Biological Evaluation ◽  
Antileishmanial Activity ◽  
Dual Effect ◽  
Design Synthesis ◽  
Murine Peritoneal Macrophages ◽  
Synthesis And Biological Evaluation

Leishmaniasis is a neglected disease that affects 12 million people living mainly in developing countries. Herein, 24 new N-oxide-containing compounds were synthesized followed by in vitro and in vivo evaluation of their antileishmanial activity. Compound 4f, a furoxan derivative, was particularly remarkable in this regard, with EC50 value of 3.6 μM against L. infantum amastigote forms and CC50 value superior to 500 μM against murine peritoneal macrophages. In vitro studies suggested that 4f may act by a dual effect, by releasing nitric oxide after biotransformation and by inhibiting cysteine protease CPB (IC50: 4.5 μM). In vivo studies using an acute model of infection showed that compound 4f at 7.7 mg/Kg reduced ~90% of parasite burden in the liver and spleen of L. infantum-infected BALB/c mice. Altogether, these outcomes highlight furoxan 4f as a promising compound for further evaluation as an antileishmanial agent.

Sign in / Sign up

Export Citation Format

Share Document